Koroukian Siran M, Bakaki Paul M, Schluchter Mark, Owusu Cynthia, Cooper Gregory S, Flocke Susan A
Case Western Reserve University; Case Comprehensive Cancer Center, Case Western Reserve University; University Hospitals of Cleveland; and Population Health and Outcomes Research Core, Clinical and Translational Science Collaborative, Cleveland, OH
Case Western Reserve University; Case Comprehensive Cancer Center, Case Western Reserve University; University Hospitals of Cleveland; and Population Health and Outcomes Research Core, Clinical and Translational Science Collaborative, Cleveland, OH.
J Oncol Pract. 2015 Nov;11(6):478-85. doi: 10.1200/JOP.2014.002634. Epub 2015 Sep 15.
To compare outcomes between women enrolling in Medicaid after being diagnosed with breast cancer and those referred to Medicaid through the Ohio Breast and Cervical Cancer Early Detection Program (BCCEDP).
Using linked data from the 2002 to 2008 Ohio Cancer Incidence Surveillance System, Medicaid, the BCCEDP database, and Ohio death certificates (through 2010), we identified women 40 to 64 years of age diagnosed with incident invasive breast cancer during the study years and enrolled in Medicaid 3 months before or after cancer diagnosis. We compared the following outcomes across BCCEDP one-time and repeat participants and nonparticipants: (1) cancer stage at diagnosis, (2) treatment delays, (3) receipt of standard treatment, and (4) survival. We conducted multivariable logistic regression and survival analysis to examine the association between BCCEDP participation and the outcomes of interest, controlling for potential confounders.
We identified 427 and 654 BCCEDP participants and nonparticipants, respectively; 28.5% of BCCEDP women were repeat participants. Compared with nonparticipants, BCCEDP one-time and repeat participants were significantly less likely to be diagnosed with advanced-stage cancer (one-time: adjusted odds ratio [AOR], 0.64; 95% CI, 0.49 to 0.85; repeat: AOR, 0.34; 95% CI, 0.23 to 0.52), or experience delays in treatment initiation (one-time: adjusted hazard ratio [AHR], 1.29; 95% CI, 1.09 to 1.51; repeat: AHR, 1.38; 95% CI, 1.11 to 1.72). In addition, although we observed no difference in receipt of standard cancer treatment, BCCEDP participants experienced cancer-specific and overall survival benefits.
Compared with nonparticipants, BCCEDP participants experienced earlier breast cancer stage at diagnosis, shorter time to treatment initiation, and survival benefits.
比较乳腺癌确诊后加入医疗补助计划的女性与通过俄亥俄州乳腺癌和宫颈癌早期检测计划(BCCEDP)加入医疗补助计划的女性之间的结局。
利用2002年至2008年俄亥俄州癌症发病率监测系统、医疗补助计划、BCCEDP数据库以及俄亥俄州死亡证明(截至2010年)的关联数据,我们确定了在研究期间确诊为侵袭性乳腺癌且在癌症诊断前3个月或后加入医疗补助计划的40至64岁女性。我们比较了BCCEDP一次性参与者、重复参与者和非参与者在以下结局方面的差异:(1)诊断时的癌症分期,(2)治疗延迟情况,(3)接受标准治疗的情况,以及(4)生存率。我们进行了多变量逻辑回归和生存分析,以检验BCCEDP参与情况与感兴趣的结局之间的关联,并控制潜在的混杂因素。
我们分别确定了427名和654名BCCEDP参与者和非参与者;28.5%的BCCEDP女性为重复参与者。与非参与者相比,BCCEDP一次性参与者和重复参与者被诊断为晚期癌症的可能性显著降低(一次性:调整后的优势比[AOR],0.64;95%置信区间,0.49至0.85;重复:AOR,0.34;95%置信区间,0.23至0.52),或者经历治疗开始延迟的可能性也显著降低(一次性:调整后的风险比[AHR],1.29;95%置信区间,1.09至1.51;重复:AHR,1.38;95%置信区间,1.11至1.72)。此外,尽管我们观察到在接受标准癌症治疗方面没有差异,但BCCEDP参与者在癌症特异性生存率和总生存率方面有获益。
与非参与者相比,BCCEDP参与者在诊断时乳腺癌分期更早,治疗开始时间更短,且有生存获益。